FundedIQ
Biotechnology

BrainChild Bio

BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors. They use CAR-T cell technology to create treatments for tumors in the central nervous system, particularly focusing on DIPG. Their research is based on previous studies at Seattle Children's Hospital and their goal is to offer new treatments for incurable brain cancers in children.

www.brainchildbio.com Seattle, United States 11-50 employees
Total raised
$300k
Rounds
1
Latest
Series Unknown
Jan 2025

BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors. They use CAR-T cell technology to create treatments for tumors in the central nervous system, particularly focusing on DIPG. Their research is based on previous studies at Seattle Children's Hospital and their goal is to offer new treatments for incurable brain cancers in children.

BrainChild Bio has raised $300k across 1 round. Its most recent round was a Series Unknown of $300k in Jan 2025. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Jan 21, 2025
Series Unknown
$300k

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

BrainChild Bio is featured in

Similar companies

Genomenon

Genomenon develops software tools to rapidly and autonomously prioritize data points for decision-making. It revolutionizes the way genetic diagnoses and discoveries are made. The company’s suite of diagnostic and discovery tools enable physicians, pharma, and researchers to quickly and accurately identify disease-causing variants from genomic-sequencing datasets. It was founded in 2014 and is headquartered in Ann Arbor, Michigan.

Series Unknown $6.0M
Adjuvia Therapeutics

Adjuvia Therapeutics is a clinical-stage biopharmaceutical company.

Seed $8.0M
CoreMap

CoreMap exists to improve patient outcomes by delivering advanced diagnostic technology to electrophysiologists and patients.

Series C $37.0M
Sonavex

Sonavex, Inc. is a Baltimore-based medical device company originally spun out of Johns Hopkins focused on Empowered Patient Care. The company has developed a portfolio of novel ultrasound solutions that empower patient care by delivering critical visual and quantitative data to improve outcomes and reduce costs. EchoMark is a bioresorbable and highly echogenic (visible under ultrasound) implant used to mark at-risk blood vessels such that the site can be easily assessed for future complications. EchoSure is a deep-learning enabled 3D automated ultrasound device designed to be used by healthcare providers without ultrasound training to assess blood flow and morphology of vessels marked by the implanted EchoMark device. For more information, please visit http://www.sonavex.com

Series Unknown $3.1M
ALZpath

ALZpath is a biotech organization that offers innovative diagnostic options for Alzheimer's disease.

Series Unknown $8.4M
Reme-D

Reme-D is a cutting-edge technology company that has patented technology, which is revolutionizing healthcare in areas with limited resources by providing cost-effective and efficient disease testing systems. This ensures that everyone has equal access to essential medical diagnostics.

Seed $1.4M
Trellis Bioscience

Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact of potential therapeutic interventions. The company is based in San Francisco, California.

Series C $9.0M
Lyora Therapeutics

Lyora Therapeutics develops genetic medicines for inherited retinal diseases that currently have no treatment.

Pre-Seed $2.5M
Wugen

Wugen is a developer of a novel CAR-T therapy platform intended for T-Cell Malignancies.The company's state-of-the-art gene editing technologies and cutting-edge Car-T cell therapy address some of the challenges that have limited the clinical development of allogeneic Car-T cells, enabling patients aid in the treatment of cancer.

Series C $35.0M
Fore Biotherapeutics

Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics. The company is creating a pipeline of precision oncology treatments aimed at patients with unaddressed mutations across well-established oncology targets.

Series D $67.4M
Kuehnle Agrosystems

Kuehnle Agrosystems, Inc. specializes in biotech research and development of plant-based systems used for producing biologically active compounds. Originally known as Kuehnle Agrosystems Company, LLC, the company was established in 2007 and is located in Honolulu, Hawaii.

Series B
Eliaz Therapeutics

ETI have fostered a protected, novel clinical gadget that eliminates galectin-3 from human blood. The gadget eliminates both bound and free galectin-3 from the course, offering another treatment choice that is less obtrusive and has less aftereffects than different treatments. The single-use apheresis segment specifically eliminates Galectin-3 from the body. It contains an exclusive, profoundly powerful catching particle and is underlying an organization that medical clinics definitely know how to utilize.

Equity Crowdfunding $40k
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.